日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors

Azenosertib 是一种强效且选择性的 WEE1 激酶抑制剂,对多种实体瘤具有广泛的抗肿瘤活性。

Jianhui Ma # ,Wen Liu # ,Jiali Li # ,Daehwan Kim ,Sangyub Kim ,Alexandra Levy ,Zhen Cai ,Kevin D Bunker ,Alejandro Recio-Boiles ,Jennifer M Segar ,Shiraj Sen ,Deborah B Doroshow ,Danielle Jandial ,Michael Rutgard ,Olivier Harismendy ,Stephan K Grant ,Ahmed A Samatar ,Kimberlee M Fischer ,Mark R Lackner

The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Models

选择性 WEE1 抑制剂 Azenosertib 在临床前模型中表现出与 KRASG12C 抑制剂的协同抗肿瘤活性

Nathan M Jameson, Daehwan Kim, Catherine Lee, Blake Skrable, Alexandra Shea, Xiao Guo, Hooman Izadi, Mona Abed, Olivier Harismendy, Jianhui Ma, Doris S Kim, Mark R Lackner

Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models

乳腺癌临床前模型中对磷脂酰肌醇 3-激酶抑制剂他塞利西布反应的预测和药效学生物标志物

Heather M Moore, Heidi M Savage, Carol O'Brien, Wei Zhou, Ethan S Sokol, Michael E Goldberg, Ciara Metcalfe, Lori S Friedman, Mark R Lackner, Timothy R Wilson

Genomic Analysis of Circulating Tumor Cells at the Single-Cell Level

单细胞水平的循环肿瘤细胞基因组分析

Shan Lu, Chia-Jung Chang, Yinghui Guan, Edith Szafer-Glusman, Elizabeth Punnoose, An Do, Becky Suttmann, Ross Gagnon, Angel Rodriguez, Mark Landers, Jill Spoerke, Mark R Lackner, Wenzhong Xiao, Yulei Wang

Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer

骨膜蛋白和反应性基质的上调与原发性化学耐药性相关,并可预测上皮性卵巢癌的临床结果

Lisa Ryner, Yinghui Guan, Ron Firestein, Yuanyuan Xiao, Younjeong Choi, Christina Rabe, Shan Lu, Eloisa Fuentes, Ling-Yuh Huw, Mark R Lackner, Ling Fu, Lukas C Amler, Carlos Bais, Yulei Wang

First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors

pictilisib (GDC-0941) 是一种强效泛 I 类磷脂酰肌醇-3-激酶 (PI3K) 抑制剂,在晚期实体肿瘤患者中开展的首次人体 I 期研究

Debashis Sarker #, Joo Ern Ang #, Richard Baird, Rebecca Kristeleit, Krunal Shah, Victor Moreno, Paul A Clarke, Florence I Raynaud, Gallia Levy, Joseph A Ware, Kathryn Mazina, Ray Lin, Jenny Wu, Jill Fredrickson, Jill M Spoerke, Mark R Lackner, Yibing Yan, Lori S Friedman, Stan B Kaye, Mika K Derync

Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing

使用靶向下一代测序分析临床福尔马林固定、石蜡包埋的结肠直肠肿瘤标本中的癌症基因突变

Liangxuan Zhang, Liangjing Chen, Sachin Sah, Gary J Latham, Rajesh Patel, Qinghua Song, Hartmut Koeppen, Rachel Tam, Erica Schleifman, Haider Mashhedi, Sreedevi Chalasani, Ling Fu, Teiko Sumiyoshi, Rajiv Raja, William Forrest, Garret M Hampton, Mark R Lackner, Priti Hegde, Shidong Jia

Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma

开发一种基于流式细胞术的强大药效学检测方法,用于检测多发性骨髓瘤中磷脂酰肌醇 3-激酶抑制剂的磷酸化蛋白信号

Congfen Li, Chikara Takahashi, Liangxuan Zhang, Mahrukh Huseni, Basha Stankovich, Haider Mashhedi, Joanna Lee, Dorothy French, Jeff Eastham Anderson, Doris Kim, Kathy Howell, Matthew J Brauer, Marcin Kowanetz, Yibing Yan, Eric Humke, Allen Ebens, Garret Hampton, Mark R Lackner, Priti Hegde, Shidong

GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway

GDC-0980 是一种新型 I 类 PI3K/mTOR 激酶抑制剂,在 PI3K 通路驱动的癌症模型中具有强大的活性

Jeffrey J Wallin, Kyle A Edgar, Jane Guan, Megan Berry, Wei Wei Prior, Leslie Lee, John D Lesnick, Cristina Lewis, Jim Nonomiya, Jodie Pang, Laurent Salphati, Alan G Olivero, Daniel P Sutherlin, Carol O'Brien, Jill M Spoerke, Sonal Patel, Letitia Lensun, Robert Kassees, Leanne Ross, Mark R Lackner, 

Molecular biomarker analyses using circulating tumor cells

使用循环肿瘤细胞进行分子生物标志物分析

Elizabeth A Punnoose, Siminder K Atwal, Jill M Spoerke, Heidi Savage, Ajay Pandita, Ru-Fang Yeh, Andrea Pirzkall, Bernard M Fine, Lukas C Amler, Daniel S Chen, Mark R Lackner